Caroline Dotolo provides in-depth counsel to public and private companies based in the United States and abroad on issues concerning debt and equity financings, mergers and acquisitions, joint ventures, SEC and listing exchange compliance, governance and general corporate law. Ms. Dotolo's industry experience includes working with clients in the financial services, life sciences, technology and telecommunications sectors.

Ms. Dotolo's practice also involves regularly advising early-stage companies on a variety of matters including formation and founder issues, equity structure, financing, and governance, as well as pro bono representation for nonprofit organizations.

The American Lawyer named Ms. Dotolo a 2023 Newest Leader in the Law in the publication’s New England Legal Awards. Honorees are recognized as extraordinary attorneys with impressive accomplishments early in their careers. In 2022, Ms. Dotolo was named to Massachusetts Lawyers Weekly’s list of Up & Coming Lawyers for distinguishing herself as a rising star in the local legal community within her first ten years of practice.

Prior to joining WilmerHale, Ms. Dotolo was an intern in the Economic Crimes Unit in the Civil Division of the US Attorney's Office in Boston. Prior to her legal education, Ms. Dotolo was a law clerk at a small firm in Ohio, assisting with various civil and criminal matters.


  • Ms. Dotolo has represented either the issuer or the underwriters in numerous IPOs, follow-on offerings and other equity and debt offerings, including the following:

    • Inozyme Pharma in its $128.8 million initial public offering, $73.1 million follow-on offering and $69 million follow-on offering
    • Curis in its $15.1 million registered direct offering
    • Disc Medicine in its $157.8 million follow-on public offering
    • Solid Biosciences in its numerous private placements, including, most recently, a $109 million private placement
    • Cue Biopharma in its $30 million private placement 
    • Syros Pharmaceuticals in its $130 million and $11.3 million private placements
    • Fulcrum Therapeutics in its $72 million initial public offering, $68.5 million private placement, $50.6 million follow-on offering and $144.2 million follow-on offering
    • Arvinas in its $459.9 million follow-on offering and $350 million private placement
    • Editas in its $215.6 million follow-on offering
    • A clinical-stage pharmaceutical company in its $52 million private placement
    • Altiostar Networks in numerous venture financings
    • Trevi Therapeutics in its $55 million initial public offering
    • Constellation Pharmaceuticals in its $60 million initial public offering
    • Flywire in numerous venture financings
    • Idera Pharmaceuticals in its $52.5 million, $57.5 million, $40 million, $27.7 million and $16.5 million follow-on offerings
    • Spark Therapeutics in its $402.5 million follow-on offering
    • An American investment management firm in its public offering of $300 million in senior notes
    • Merrimack Pharmaceuticals in its 144A offering of $175 million in senior notes
    • Bellerophon Therapeutics in its $60 million initial public offering  
  • Ms. Dotolo regularly advises public companies in the establishment of "at-the-market" sales arrangements, PIPEs and strategic equity transactions.
  • Ms. Dotolo also represents private companies in various stages of development, including in venture capital and strategic financings.


  • Named a Newest Leader in the Law by The American Lawyer's New England Legal Awards (2023). 
  • Named to Massachusetts Lawyers Weekly's 2022 list of Up & Coming lawyers.
  • Named to Boston Magazine’s Top Lawyers list in 2023 in the area of corporate law.

Insights & News


  • Education

    • JD, Boston University School of Law, 2012

      Boston University Law Review, Co-Director, Student Advisor Program, Women’s Law Association
    • BA, History and Sociology, The Ohio State University, 2008

      magna cum laude Honors Program
    • Harvard Business School Online

      Credential of Readiness (CORe), Business Analytics, Financial Accounting, Economics for Managers, with High Honors, 2015

  • Admissions

    • Massachusetts



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.